help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2007-1447
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
149/5/2546    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Crowe, S.
Right arrow Articles by Watt, M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crowe, S.
Right arrow Articles by Watt, M. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Nutrition
*Obesity
Endocrinology Vol. 149, No. 5 2546-2556
Copyright © 2008 by The Endocrine Society

Metabolic Remodeling in Adipocytes Promotes Ciliary Neurotrophic Factor-Mediated Fat Loss in Obesity

Seamus Crowe, Sarah M. Turpin, Francine Ke, Bruce E. Kemp and Matthew J. Watt

St. Vincent’s Institute of Medical Research and the Department of Medicine (S.C., S.M.T., F.K., B.E.K., M.J.W.), The University of Melbourne, Fitzroy, Victoria 3065, Australia; and Commonwealth Scientific and Industrial Research Organization Molecular Health Technologies (B.E.K.), Parkville, Victoria 3052, Australia

Address all correspondence and requests for reprints to: Matthew J. Watt, Ph.D., Department of Physiology, Monash University, Clayton, Victoria 3800, Australia. E-mail: matthew.watt{at}med.monash.edu.au.

Obesity is characterized by an expanded adipose tissue mass, and reversing obesity reduces the risk of insulin resistance and cardiovascular disease. Ciliary neurotrophic factor (CNTF) reverses obesity by promoting the preferential loss of white adipose tissue. We evaluated the cellular and molecular mechanisms by which CNTF regulates adiposity. Obese mice fed a high-fat diet were treated with saline or recombinant CNTF for 10 d, and adipose tissue was removed for analysis. Another group fed a high-fat diet was pair fed to CNTF mice. In separate experiments, 3T3-L1 adipocytes were treated with CNTF to examine metabolic responses and signaling. CNTF reduced adipose mass that resulted from reductions in adipocyte area and triglyceride content. CNTF treatment did not affect lipolysis but resulted in decreases in fat esterification and lipogenesis and enhanced fatty acid oxidation. The enhanced fat oxidation was associated with the expression of peroxisome proliferator-activated receptor coactivator-1{alpha} (PGC1{alpha}) and nuclear respiratory factor 1 and increases in oxidative phosphorylation subunits and mitochondrial biogenesis as determined by electron microscopy. Studies in cultured adipocytes revealed that CNTF activates p38 MAPK and AMP-activated protein kinase. Inhibiting p38 activation prevented the CNTF-induced increase in PGC1{alpha} but not AMP-activated protein kinase activation. Diminished food intake with pair feeding induced similar decreases in fat mass, but this was related to increased expression of uncoupling protein 1. We conclude that CNTF reprograms adipose tissue to promote mitochondrial biogenesis, enhancing oxidative capacity and reducing lipogenic capacity, thereby resulting in triglyceride loss.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society